Founders Financial Securities LLC Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

Founders Financial Securities LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 78.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,856 shares of the biopharmaceutical company’s stock after selling 51,071 shares during the quarter. Founders Financial Securities LLC’s holdings in Pfizer were worth $384,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, June 26th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $35.54.

Pfizer Trading Up 0.6 %

PFE opened at $27.98 on Monday. The firm has a market cap of $158.55 billion, a price-to-earnings ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The business’s 50 day moving average is $27.90 and its two-hundred day moving average is $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.